These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3178380)

  • 41. [Acute pleuropulmonary complication following an injection of an anti-inflammatory agent].
    Brodersen HC; Lang KF; Bose E; Schuster HP; Just HG
    Poumon Coeur; 1970; 26(9):1075-8. PubMed ID: 5518899
    [No Abstract]   [Full Text] [Related]  

  • 42. Treatment of parkinson's disease with bromocriptine.
    Lieberman A; Kupersmith M; Estey E; Goldstein M
    N Engl J Med; 1976 Dec; 295(25):1400-4. PubMed ID: 989885
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interaction between lansoprazole and bromocriptine in a patient with Parkinson's disease.
    Anglès A; Bagheri H; Saivin S; Montastruc JL
    Therapie; 2002; 57(4):408-10. PubMed ID: 12422563
    [No Abstract]   [Full Text] [Related]  

  • 45. [Bromocriptine as the 1st treatment of Parkinson's disease. Long term results].
    Rascol A; Montastruc JL; Guiraud-Chaumeil B; Clanet M
    Rev Neurol (Paris); 1982; 138(5):401-8. PubMed ID: 7146724
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Retroperitoneal fibrosis in two patients with Parkinson's disease treated with bromocriptine.
    Kains JP; Hardy JC; Chevalier C; Collier A
    Acta Clin Belg; 1990; 45(5):306-10. PubMed ID: 2177299
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The response of "de novo" Parkinson's disease patients to bromocriptine in a "low and slow" regimen is predictive for prognosis.
    Sampaio C; Coelho T; Castro-Caldas A; Bastos-Lima A; Levy A
    J Neural Transm Suppl; 1995; 45():197-202. PubMed ID: 8748626
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I; Gawel MJ; Riopelle RJ; Bouchard S
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sustained bromocriptine therapy in 50 previously untreated patients with Parkinson's disease.
    Stern GM; Lees AJ
    Adv Neurol; 1983; 37():17-21. PubMed ID: 6858771
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
    Grimes JD; Delgado MR
    Clin Neuropharmacol; 1985; 8(1):73-7. PubMed ID: 3978651
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Treatment of Parkinson's disease with bromocriptine].
    Castaigne P; Laplane D; Bousser MG; Bories F
    Nouv Presse Med; 1976 Apr; 6(17):1482. PubMed ID: 1037400
    [No Abstract]   [Full Text] [Related]  

  • 52. [Pleuropulmonary changes during treatment with bromocriptine].
    Ugeskr Laeger; 1988 May; 150(18):1124. PubMed ID: 3368987
    [No Abstract]   [Full Text] [Related]  

  • 53. [Neuropsychic side effects of bromocriptine in Parkinson's disease].
    Simonetta M; Schmitt L; Montastruc JL; Rascol A
    Rev Neurol (Paris); 1987; 143(8-9):608-11. PubMed ID: 3671965
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bromocriptine and pleuropulmonary disease.
    Melmed S; Braunstein GD
    Arch Intern Med; 1989 Feb; 149(2):258-9. PubMed ID: 2916870
    [No Abstract]   [Full Text] [Related]  

  • 55. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pleuropulmonary necrobiotic rheumatoid nodules. A review and clinicopathological study of six patients.
    Walters MN; Ojeda VJ
    Med J Aust; 1986 Jun; 144(12):648-51. PubMed ID: 3713605
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term treatment with high-dosage bromocriptine in advanced Parkinson's disease.
    Jansen EN; Meerwaldt JD
    Adv Neurol; 1987; 45():539-42. PubMed ID: 3103396
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
    Grosset K; Needleman F; Macphee G; Grosset D
    Mov Disord; 2004 Nov; 19(11):1370-4. PubMed ID: 15389984
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Combined treatment of the early stages of Parkinson's syndrome with bromocriptine and levodopa. The results of a multicenter study].
    Fischer PA; Przuntek H; Majer M; Welzel D
    Dtsch Med Wochenschr; 1984 Aug; 109(34):1279-83. PubMed ID: 6381019
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pleuropulmonary shadows on bromocriptine.
    Besser GM; Wass JA
    Lancet; 1981 Feb; 1(8215):323. PubMed ID: 6109954
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.